Haohai Biotechnology (06826) will pay a final dividend of 1 yuan per share on July 19

Haohai Biotechnology (06826) issued an announcement that it will be distributed on July 19, 2024 until 2024 until 2023...

Zhitong FinanceApr 26 19:52

Haohai Biotechnology (06826.HK) plans to hold a board meeting on April 29 to approve the first quarter results

Gelonghui, April 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.

Gelonghui FinanceApr 17 16:42

Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption

The company is a leader in the biomaterials segment, opening up a development ceiling for incremental ophthalmology and medical and aesthetic business layouts. Established in 2007, Haohai Biotech is mainly engaged in R&D, production and sales of medical device products. The company uses a “self-development+acquisition” policy

民生證券Apr 17 16:41

昊海生物科技：董事會會議召開日期

Futu NewsApr 17 16:37 · Announcements

Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili

Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceiling for the incremental ophthalmology and medical aesthetic business layout; 2) the ophthalmology and medical aesthetic market continues to grow rapidly, driven by internal and external factors, and iterations of innovative products drive the sustainability of the industry's growth; 3) the company has a comprehensive business layout and strong competitiveness in the ophthalmology and aesthetic business. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 17 16:18

HAOHAI BIOTEC: ANNUAL REPORT 2023

Futu NewsApr 12 17:04 · Announcements